Vincent Capponi - 14 Sep 2026 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Reporting relationship: President and COO
Issuer ticker: CTSO
Reported as of: 14 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Sep 2026, 16:05:30 UTC
Prior SEC filing: 08 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Peter J. Mariani attorney-in-fact Vincent Capponi

Key filing fact

Vincent Capponi filed Form 4 for Cytosorbents Corp (CTSO) on 16 Sep 2026.

Key facts

This page summarizes Vincent Capponi's Form 4 filing for Cytosorbents Corp (CTSO).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 16 Sep 2026, 16:05.

Change

Previous filing in this sequence was filed on 08 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001368151 Primary reporting owner

Capponi Vincent

Relationship: President and COO
Address: C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON
Signature: /s/ Peter J. Mariani attorney-in-fact Vincent Capponi
Signature date: 16 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTSO transaction

Common Stock

Purchase

Transaction value
Shares: +1,800
Change %: +4.7%
Price: $6.07^*
Shares after: 40,114
Date: 14 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4, F5

CTSO transaction

Common Stock

Purchase

Transaction value
Shares: +273
Change %: +0.68%
Price: $5.90^*
Shares after: 40,387
Date: 14 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person.

Footnote F2

Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 505 RSUs granted on March 15, 2018, (b) 895 RSUs granted on February 24, 2017, (c) 2,700 RSUs granted on June 7, 2016 and (d) 6,250 RSUs granted on April 8, 2015;

Footnote F3

(continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 4,455 RSUs granted on August 8, 2025 and of which 2,228 remain unvested as of the date hereof; and

Footnote F4

(continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person.

Footnote F5

Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.